Omonigho M Bubu1,2, Ogie Q Umasabor-Bubu3, Arlener D Turner1, Ankit Parekh4, Anna E Mullins4, Korey Kam4, Madeline K Birckbichler5, Fahad Mukhtar6, Alfred K Mbah6, Natasha J Williams2, David M Rapoport4, Mony de Leon7, Girardin Jean-Louis2, Indu Ayappa4, Andrew W Varga4, Ricardo S Osorio1,8. 1. Center for Sleep and Brain Health, Department of Psychiatry, NYU Grossman School of Medicine, New York, New York, USA. 2. Center for Healthful Behavior Change, Department of Population Health, New York Grossman School of Medicine, New York, USA. 3. Department of Epidemiology and Infection Control, State University New York Downstate Medical Center, Brooklyn, New York, USA. 4. Division of Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York, USA. 5. Department of Applied Health Sciences, Wheaton College, Wheaton, Illinois, USA. 6. Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, Florida, USA. 7. Brain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York, USA. 8. Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA.
Abstract
INTRODUCTION: Obstructive sleep apnea (OSA) is associated with Alzheimer's disease (AD) biomarkers in cognitively normal (CN) and mild cognitive impaired (MCI) participants. However, independent and combined effects of OSA, amyloid beta (Aβ) and tau-accumulation on AD time-dependent progression risk is unclear. METHODS: Study participants grouped by biomarker profile, as described by the A/T/N scheme, where "A" refers to aggregated Aβ, "T" aggregated tau, and "N" to neurodegeneration, included 258 CN (OSA-positive [OSA+] [A+TN+ n = 10, A+/TN- n = 6, A-/TN+ n = 10, A-/TN- n = 6 and OSA-negative [OSA-] [A+TN+ n = 84, A+/TN- n = 11, A-/TN+ n = 96, A-/TN- n = 36]) and 785 MCI (OSA+ [A+TN+ n = 35, A+/TN- n = 15, A-/TN+ n = 25, A-/TN- n = 16] and OSA- [A+TN+ n = 388, A+/TN- n = 28, A-/TN+ n = 164, A-/TN- n = 114]) older-adults from the Alzheimer's Disease Neuroimaging Initiative cohort. Cox proportional hazards regression models estimated the relative hazard of progression from CN-to-MCI and MCI-to-AD, among baseline OSA CN and MCI patients, respectively. Multi-level logistic mixed-effects models with random intercept and slope investigated the synergistic associations of self-reported OSA, Aβ, and tau burden with prospective cognitive decline. RESULTS: Independent of TN-status (CN and MCI), OSA+/Aβ+ participants were approximately two to four times more likely to progress to MCI/AD (P < .001) and progressed 6 to 18 months earlier (P < .001), compared to other participants combined (ie, OSA+/Aβ-, OSA-/Aβ+, and OSA-/Aβ-). Notably, OSA+/Aβ- versus OSA-/Aβ- (CN and MCI) and OSA+/TN- versus OSA-/TN- (CN) participants showed no difference in the risk and time-to-MCI/AD progression. Mixed effects models demonstrated OSA synergism with Aβ (CN and MCI [β = 1.13, 95% confidence interval (CI), 0.74 to 1.52, and β = 1.18, 95%CI, 0.82 to 1.54]) respectively, and with tau (MCI [β = 1.31, 95% CI, 0.87 to 1.47]), P < .001 for all. DISCUSSION: OSA acts in synergism with Aβ and with tau, and all three acting together result in synergistic neurodegenerative mechanisms especially as Aβ and tau accumulation becomes increasingly abnormal, thus leading to shorter progression time to MCI/AD in CN and MCI-OSA patients, respectively.
INTRODUCTION: Obstructive sleep apnea (OSA) is associated with Alzheimer's disease (AD) biomarkers in cognitively normal (CN) and mild cognitive impaired (MCI) participants. However, independent and combined effects of OSA, amyloid beta (Aβ) and tau-accumulation on AD time-dependent progression risk is unclear. METHODS: Study participants grouped by biomarker profile, as described by the A/T/N scheme, where "A" refers to aggregated Aβ, "T" aggregated tau, and "N" to neurodegeneration, included 258 CN (OSA-positive [OSA+] [A+TN+ n = 10, A+/TN- n = 6, A-/TN+ n = 10, A-/TN- n = 6 and OSA-negative [OSA-] [A+TN+ n = 84, A+/TN- n = 11, A-/TN+ n = 96, A-/TN- n = 36]) and 785 MCI (OSA+ [A+TN+ n = 35, A+/TN- n = 15, A-/TN+ n = 25, A-/TN- n = 16] and OSA- [A+TN+ n = 388, A+/TN- n = 28, A-/TN+ n = 164, A-/TN- n = 114]) older-adults from the Alzheimer's Disease Neuroimaging Initiative cohort. Cox proportional hazards regression models estimated the relative hazard of progression from CN-to-MCI and MCI-to-AD, among baseline OSA CN and MCI patients, respectively. Multi-level logistic mixed-effects models with random intercept and slope investigated the synergistic associations of self-reported OSA, Aβ, and tau burden with prospective cognitive decline. RESULTS: Independent of TN-status (CN and MCI), OSA+/Aβ+ participants were approximately two to four times more likely to progress to MCI/AD (P < .001) and progressed 6 to 18 months earlier (P < .001), compared to other participants combined (ie, OSA+/Aβ-, OSA-/Aβ+, and OSA-/Aβ-). Notably, OSA+/Aβ- versus OSA-/Aβ- (CN and MCI) and OSA+/TN- versus OSA-/TN- (CN) participants showed no difference in the risk and time-to-MCI/AD progression. Mixed effects models demonstrated OSA synergism with Aβ (CN and MCI [β = 1.13, 95% confidence interval (CI), 0.74 to 1.52, and β = 1.18, 95%CI, 0.82 to 1.54]) respectively, and with tau (MCI [β = 1.31, 95% CI, 0.87 to 1.47]), P < .001 for all. DISCUSSION: OSA acts in synergism with Aβ and with tau, and all three acting together result in synergistic neurodegenerative mechanisms especially as Aβ and tau accumulation becomes increasingly abnormal, thus leading to shorter progression time to MCI/AD in CN and MCI-OSA patients, respectively.
Authors: Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon Journal: Neurobiol Aging Date: 2007-09-24 Impact factor: 4.673
Authors: Terri-Ellen J Kiernan; Dan J Capampangan; Mark G Hickey; Lesly A Pearce; Maria I Aguilar Journal: Neurologist Date: 2011-09 Impact factor: 1.398
Authors: Jon B Toledo; Maria Bjerke; Xiao Da; Susan M Landau; Norman L Foster; William Jagust; Clifford Jack; Michael Weiner; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski Journal: JAMA Neurol Date: 2015-05 Impact factor: 18.302
Authors: Julia F Van Den Berg; Frank J A Van Rooij; Henk Vos; Joke H M Tulen; Albert Hofman; Henk M E Miedema; Arie Knuistingh Neven; Henning Tiemeier Journal: J Sleep Res Date: 2008-02-27 Impact factor: 3.981
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Howard H Feldman; Giovanni B Frisoni; Harald Hampel; William J Jagust; Keith A Johnson; David S Knopman; Ronald C Petersen; Philip Scheltens; Reisa A Sperling; Bruno Dubois Journal: Neurology Date: 2016-07-01 Impact factor: 9.910
Authors: Diego Z Carvalho; Erik K St Louis; Christopher G Schwarz; Val J Lowe; Bradley F Boeve; Scott A Przybelski; Ashritha Reddy; Michelle M Mielke; David S Knopman; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Neurology Date: 2020-03-26 Impact factor: 9.910
Authors: M J Duncan; L E Guerriero; K Kohler; L E Beechem; B D Gillis; F Salisbury; C Wessel; J Wang; S Sunderam; A D Bachstetter; B F O'Hara; M P Murphy Journal: Neuroscience Date: 2021-11-29 Impact factor: 3.590
Authors: Omonigho M Bubu; Ellita T Williams; Ogie Q Umasabor-Bubu; Sonya S Kaur; Arlener D Turner; Judite Blanc; Jaime Ramos Cejudo; Anna E Mullins; Ankit Parekh; Korey Kam; Zainab T Osakwe; Ann W Nguyen; Antoine R Trammell; Alfred K Mbah; Mony de Leon; David M Rapoport; Indu Ayappa; Gbenga Ogedegbe; Girardin Jean-Louis; Arjun V Masurkar; Andrew W Varga; Ricardo S Osorio Journal: Front Aging Neurosci Date: 2021-12-10 Impact factor: 5.750